2003
DOI: 10.1007/s00280-003-0580-5
|View full text |Cite
|
Sign up to set email alerts
|

Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
39
2
8

Year Published

2004
2004
2017
2017

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 78 publications
(55 citation statements)
references
References 13 publications
1
39
2
8
Order By: Relevance
“…Butyrate and butyric acid derivatives are well known to induce differentiation and apoptosis of neoplastic cells 37,38,43 and have therefore gained acceptance as potential anticancer agents. 39,40,[44][45][46] In this study, we have demonstrated that tributyrin also has the capacity to downregulate the cellular activity of human neonatal fibroblasts. The incorporation of tributyrin within a fibrin gel provided for a delayed-release system thus allowing not only for the partial retention of tributyrin at the treatment site but also sufficient accessibility within the first days after administration.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Butyrate and butyric acid derivatives are well known to induce differentiation and apoptosis of neoplastic cells 37,38,43 and have therefore gained acceptance as potential anticancer agents. 39,40,[44][45][46] In this study, we have demonstrated that tributyrin also has the capacity to downregulate the cellular activity of human neonatal fibroblasts. The incorporation of tributyrin within a fibrin gel provided for a delayed-release system thus allowing not only for the partial retention of tributyrin at the treatment site but also sufficient accessibility within the first days after administration.…”
Section: Discussionmentioning
confidence: 99%
“…[36][37][38] Furthermore, early clinical studies have shown tributyrin to be a safe and well-tolerated alternative to butyric acid in the treatment of patients with solid tumors. 39,40 In this study, we exploited the antiproliferative effects of tributyrin to further enhance the adhesion barrier properties of fibrin sealant, thereby limiting the possibility of dural contact and subsequent adhesion formation.…”
Section: Introductionmentioning
confidence: 99%
“…While BA has poor plasma pharmacokinetics in rodents (Egorin et al, 1999), 4PBA has better pharmacokinetics in vivo (Berg et al, 2001). Similarly, glyceryl tributyrate (BA3G; tributyrin) is a BA prodrug with a glycerol backbone and improved pharmacokinetics (Edelman et al, 2003; Egorin et al , 1999). BA3G inhibits tumor growth in various cancer models (Kuefer et al, 2004) and had undergone phase I clinical trials in patients with solid tumors (Conley et al, 1998).…”
Section: Introductionmentioning
confidence: 99%
“…Dessa forma, torna-se favorável a utilização de pró-fármaco do AB, a tributirina (T). Essa substância apresenta meia-vida mais prolongada que seu produto AB e pode ser incorporada em emulsões ou cápsulas, de modo a facilitar sua administração oral e o uso em longo prazo (CONLEY et al, 1998;WATKINS et al, 1999;EDELMAN et al, 2003).…”
Section: Lista De Figurasunclassified